Cardiol Therapeutics Inc. - Class A Common Shares (NQ: CRDL )
1.150
+0.030
(+2.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
All News about Cardiol Therapeutics Inc. - Class A Common Shares
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
Via Newsfile
Exposures
Product Safety
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via Get News
Topics
Death
Exposures
Death

Cardiol Therapeutics (NASDAQ: CRDL)
Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via News Direct
Topics
Death
Exposures
Death
Cardiol Therapeutics (NASDAQ: CRDL)
Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via TheNewswire.com
Topics
Death
Exposures
Death


Via Benzinga
Via Newsfile

Via Newsfile

Sidoti's Micro-Cap Virtual May Conference
May 09, 2023
Via ACCESSWIRE


Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022

Why Orphan Drug Designation Offers Several Benefits
May 18, 2022
Exposures
Product Safety


Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free